价格

Cassava Sciences, Inc.

ACTIVE

7801 N Capital OF Texas Hwy Ste 260, 德克萨斯州奥斯汀县, Texas, 美国www.cassavasciences.comPublic29 名员工成立于: 1998-01-01

概览

试验阶段分布

阶段

试验数

占比

1 期

33.3%

2 期

33.3%

3 期

33.3%

试验状态分布

已完成

66.7%

终止

33.3%

药物批准

暂无批准数据

资讯

Alzheimer's Disease Pipeline Shows Promise with 120+ Therapies in Development

• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases. • Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact. • MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned. • The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.

Dec 9, 2024

返回机构列表

Cassava Sciences, Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（9）

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

药物批准

资讯

Alzheimer's Disease Pipeline Shows Promise with 120+ Therapies in Development